Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selonsertib - Gilead Sciences

Next Previous
Search
Drug Profile

Selonsertib - Gilead Sciences

Alternative Names: ASK1 inhibitor - Gilead Sciences; GS-4977; GS-4997

Latest Information Update: 16 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Anti-inflammatories; Antihypertensives; Benzamides; Cardiovascular therapies; Imidazoles; Pyridines; Triazoles
  • Mechanism of Action MAP kinase kinase kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alcoholic hepatitis; Diabetic nephropathies; Kidney disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Pulmonary arterial hypertension

Most Recent Events

  • 21 Jun 2023 Pharmacodynamics data from pooled analysis from two phase III trial in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
  • 28 Apr 2022 Discontinued - Phase-II for Diabetic nephropathies in Canada, USA, New Zealand, Australia, Japan, United Kingdom, Italy, Spain (PO)
  • 03 Sep 2021 Gilead Sciences completes the phase II MOSAIC trial in Diabetic nephropathies in USA, Canada, New Zealand, Australia, Japan, Spain, Italy, and United Kingdom (PO) (NCT04026165)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top